• Comprehensive Analysis Supports SERMs for Cutting Breast Cancer

    Meta-analysis shows reduced incidence of breast cancer, especially in first five years of follow-up
    TUESDAY, April 30 (HealthDay News) -- Treatment with selective estrogen receptor modulators (SERMs) is associated with a significant reduction in the incidence of breast cancer, especially for the first five years after treatment, according to research described as the first comprehensive analysis, published online April 30 in The Lancet.
    Jack Cuzick, Ph.D., from the Queen Mary University of London, and colleagues conducted a meta-analysis using data from nine prevention trials to examine the effectiveness of SERMs on the incidence of breast cancer. Data were analyzed for 83,399 women who were followed for a mean of 65 months for a total of 306,617 women-years of follow-up.
    The researchers found that there was a significant, 38 percent reduction overall in the incidence of breast cancer, and that within the first 10 years of follow-up, 42 women needed to be treated to prevent one breast cancer event. In the first five years of follow-up, the reduction was larger than in years five to 10 (hazard ratio, 0.58), but there was no heterogeneity between time periods. With all SERMS, the likelihood of thromboembolic events was significantly increased (odds ratio [OR], 1.73). There was a significant reduction in vertebral fractures (OR, 0.66), while the reduction for non-vertebral fractures was smaller, but still significant (OR, 0.93).
    "For all SERMs, incidence of invasive estrogen-positive breast cancer was reduced both during treatment and for at least five years after completion," the authors write. "Similar to other preventive interventions, careful consideration of risks and benefits is needed to identify women who are most likely to benefit from these drugs."
    One author disclosed financial ties to AstraZeneca; two authors disclosed ties to Eli Lilly.
    Abstract (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60140-3/abstract )Full Text (subscription or payment may be required) (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60140-3/fulltext )Editorial (subscription or payment may be required) (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60443-2/fulltext )
  • LiveWell personal health survey

    How healthy are you really? Find out – free.Learn more

    It's time to stop guessing. If you want to make some changes but just aren't sure how, the free personal health survey from LiveWell is a great place to start.

  • HeartSHAPE Spotlight

    At risk for a heart attack? Learn more

    Fight heart disease and prevent heart attacks. HeartSHAPE® is a painless, non-invasive test that checks pictures of your heart for early-stage coronary disease.

  • Calories and Energy Needs

    Calorie NeedsLearn more

    How many calories do you need to eat each day to maintain your weight and fuel your physical activity? Enter a few of your stats into this calculator to find out.

  • Ideal Body Weight

    Ideal Body WeightLearn more

    Using body mass index as a reference, this calculator determines your ideal body weight range. All you need to do is enter your height.

  • Body Mass Index

    Body Mass IndexLearn more

    This tool considers your height and weight to assess your weight status.

  • Can we help answer your questions?

    Wellmont Nurse Connection is your resource for valuable health information any time, 24 hours a day, seven days a week. Speak to a Nurse any time, day or night, at (423) 723-6877 or toll-free at 1-877-230-NURSE.